JP2013216685A5 - - Google Patents

Download PDF

Info

Publication number
JP2013216685A5
JP2013216685A5 JP2013141285A JP2013141285A JP2013216685A5 JP 2013216685 A5 JP2013216685 A5 JP 2013216685A5 JP 2013141285 A JP2013141285 A JP 2013141285A JP 2013141285 A JP2013141285 A JP 2013141285A JP 2013216685 A5 JP2013216685 A5 JP 2013216685A5
Authority
JP
Japan
Prior art keywords
vlp
influenza
derived
proteins
drug substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013141285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013216685A (ja
Filing date
Publication date
Priority claimed from US10/617,569 external-priority patent/US8592197B2/en
Application filed filed Critical
Publication of JP2013216685A publication Critical patent/JP2013216685A/ja
Publication of JP2013216685A5 publication Critical patent/JP2013216685A5/ja
Withdrawn legal-status Critical Current

Links

JP2013141285A 2003-07-11 2013-07-05 機能的インフルエンザウイルス様粒子（ｖｌｐ） Withdrawn JP2013216685A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/617,569 US8592197B2 (en) 2003-07-11 2003-07-11 Functional influenza virus-like particles (VLPs)
US10/617,569 2003-07-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010208644A Division JP2011046715A (ja) 2003-07-11 2010-09-16 機能的インフルエンザウイルス様粒子（ｖｌｐ）

Publications (2)

Publication Number Publication Date
JP2013216685A JP2013216685A (ja) 2013-10-24
JP2013216685A5 true JP2013216685A5 (enExample) 2014-08-21

Family

ID=33565000

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006518925A Withdrawn JP2007529997A (ja) 2003-07-11 2004-07-09 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2010208644A Pending JP2011046715A (ja) 2003-07-11 2010-09-16 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2013141285A Withdrawn JP2013216685A (ja) 2003-07-11 2013-07-05 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2014258346A Withdrawn JP2015057447A (ja) 2003-07-11 2014-12-22 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2016110634A Pending JP2016164195A (ja) 2003-07-11 2016-06-02 機能的インフルエンザウイルス様粒子（ｖｌｐ）

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2006518925A Withdrawn JP2007529997A (ja) 2003-07-11 2004-07-09 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2010208644A Pending JP2011046715A (ja) 2003-07-11 2010-09-16 機能的インフルエンザウイルス様粒子（ｖｌｐ）

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014258346A Withdrawn JP2015057447A (ja) 2003-07-11 2014-12-22 機能的インフルエンザウイルス様粒子（ｖｌｐ）
JP2016110634A Pending JP2016164195A (ja) 2003-07-11 2016-06-02 機能的インフルエンザウイルス様粒子（ｖｌｐ）

Country Status (19)

Country Link
US (5) US8592197B2 (enExample)
EP (2) EP2343084B1 (enExample)
JP (5) JP2007529997A (enExample)
KR (1) KR101153929B1 (enExample)
CN (3) CN107513102A (enExample)
AT (1) ATE538810T1 (enExample)
AU (1) AU2004268510B2 (enExample)
BR (1) BRPI0412519A (enExample)
CA (1) CA2532335C (enExample)
DK (2) DK2343084T3 (enExample)
ES (2) ES2422580T3 (enExample)
IL (1) IL173071A (enExample)
MX (1) MXPA06000469A (enExample)
NZ (1) NZ544580A (enExample)
PL (2) PL2343084T3 (enExample)
PT (2) PT2343084E (enExample)
RU (1) RU2369405C2 (enExample)
SG (2) SG131116A1 (enExample)
WO (1) WO2005020889A2 (enExample)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
US8206950B2 (en) * 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
US8992939B2 (en) 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
AU2005274649B2 (en) * 2004-08-19 2010-09-09 University College Cardiff Consultants Limited Preparation of antigen-presenting human gamma delta T cells and use in immunotherapy
US20090208517A1 (en) * 2004-08-19 2009-08-20 Bernhard Moser Preparation Of Antigen-Presenting Human Gamma-Delta T Cells And Use In Immunotherapy
EP2573185A3 (en) * 2005-02-16 2013-06-05 Lentigen Corporation Lentiviral vectors and their use
NZ583564A (en) 2005-04-21 2011-09-30 Univ Florida Materials and Methods For Respiratory Disease Control in Canines
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
SI1937301T1 (sl) * 2005-10-18 2015-08-31 Novavax, Inc. Funkcionalni influenčnemu virusu podobni delci (VLP)
EP2407480B1 (en) 2005-10-19 2014-07-16 University of Florida Research Foundation, Incorporated Materials for respiratory disease control in canines
US20070092871A1 (en) * 2005-10-20 2007-04-26 Combimatrix Corporation Microarray for pathogen identification
GB2432419A (en) * 2005-11-16 2007-05-23 Agency Science Tech & Res Influenza A virus detection method
FI20051255A0 (fi) * 2005-12-05 2005-12-05 Pekka Untamo Heino Seuraavaa influenssa A-pandemiaa vastaan soveltuva rokote
US8232058B2 (en) * 2006-01-20 2012-07-31 Lawrence Livermore National Security, Llc Multiplex detection of respiratory pathogens
SG169375A1 (en) * 2006-02-02 2011-03-30 Globeimmune Inc Yeast-based vaccine for inducing an immune response
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
AU2007224034B2 (en) * 2006-03-07 2012-03-29 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007126788A2 (en) * 2006-03-27 2007-11-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the treatment and prevention of viral infection
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
US9101578B2 (en) * 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
EP1998814A4 (en) * 2006-05-11 2010-06-16 Novavax Inc NEW VACCINES AGAINST INFLUENZA M2
KR100702034B1 (ko) * 2006-05-12 2007-03-30 삼성전자주식회사 반도체 장치, 이 장치의 전원 노이즈 감소 방법 및 인쇄회로 기판
CA2659592C (en) 2006-07-14 2016-10-04 Konstantin V. Pugachev Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
US20100047266A1 (en) * 2006-07-27 2010-02-25 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
AU2007345768B2 (en) 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
US8097419B2 (en) * 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US20090098527A1 (en) * 2006-09-12 2009-04-16 Fischer Gerald W Biological organism identification product and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
EP2601969B1 (en) * 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
EP2069483A4 (en) * 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRAL VECTORS
EP2069503B1 (en) * 2006-11-15 2016-01-06 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
AU2009202819B2 (en) * 2007-07-13 2014-08-28 Aramis Biotechnologies Inc. Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
EP2175883A4 (en) * 2007-07-19 2011-11-30 Novavax Inc CHIMERIC VARICELLA ZOSTER VIRUS-VIRUSUAL PARTICLES
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
CA2976814C (en) 2007-08-27 2022-12-13 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods for treating influenza
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US10130696B2 (en) 2007-09-18 2018-11-20 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
AU2008343745B2 (en) 2007-10-01 2012-05-10 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
EA034733B1 (ru) * 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
WO2009102229A1 (ru) * 2008-02-15 2009-08-20 A.N. Belozersky Institute Of Physico-Chemical Biology, Moscow State University Липид-протеиновый рафтовый комплекс из оболочки вируса гриппа а для противогриппозных вакцин и способ его выделения, способ получения вирусоподобных частиц из таких комплексов
BRPI0910464B1 (pt) 2008-04-17 2021-08-10 Pds Biotechnology Corporation Uso de uso de um lipídio catiônico quiral consistindo de r-dotap a preparação de composição farmacêutica
ES2594102T3 (es) * 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
US8486619B2 (en) * 2008-05-02 2013-07-16 University Of Rochester Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses
US8450056B2 (en) * 2008-05-02 2013-05-28 University Of Rochester Arrayed imaging reflectometry (AIR) sensor chip comprising virus-like particles suitable for the detection of antiviral immune responses
CN101293099B (zh) * 2008-06-04 2010-12-08 厦门大学 一种抗多种亚型禽流感病毒的多肽疫苗及其制备方法
EP2294202B1 (en) 2008-07-08 2015-05-20 Medicago Inc. Soluble recombinant influenza antigens
PT2318530T (pt) * 2008-07-18 2016-09-30 Medicago Inc Novo epítopo de imunização contra o vírus da gripe
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
IT1394782B1 (it) 2009-03-03 2012-07-13 Alenia Aeronautica Spa Procedimento di predizione di collisioni tra un velivolo e un aeromobile
JP2012521786A (ja) * 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
NZ595710A (en) * 2009-05-01 2013-10-25 Redbiotec Ag Recombinant virus-like particles encoded by multi-gene vector
EP2435475B1 (en) 2009-05-26 2018-10-17 Icahn School of Medicine at Mount Sinai Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
CN102482328B (zh) 2009-06-24 2014-11-26 麦迪卡格公司 包含血凝素的嵌合流感病毒样颗粒
US9278998B2 (en) 2009-07-02 2016-03-08 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
SI2480560T1 (en) 2009-09-22 2018-04-30 Medicago Inc. A process for preparing proteins derived from plants
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
EP2496609A4 (en) 2009-11-03 2013-05-08 Ligocyte Pharmaceuticals Inc CHIMERIC RSV-F POLYPEPTIDE AND VLPS ON LENTIVIREN OR ALPHA RETROVIRUS GAG BASE
US9352031B2 (en) * 2010-02-18 2016-05-31 Technovax, Inc. Universal virus-like particle (VLP) influenza vaccines
AU2011217903B2 (en) 2010-02-18 2017-03-02 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
NZ602217A (en) 2010-03-11 2014-08-29 Immune Design Corp Vaccines for influenza
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN102373184A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性支气管炎混合病毒样颗粒、制备方法和应用
CN102373182A (zh) * 2010-08-09 2012-03-14 中山大学 禽流感和传染性囊病混合病毒样颗粒、制备方法和应用
US8802110B2 (en) 2010-09-21 2014-08-12 Massachusetts Institute Of Technology Influenza treatment and/or characterization, human-adapted HA polypeptides; vaccines
HUE069586T2 (hu) 2010-10-01 2025-03-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak, valamint ezek felhasználása
CA2813078A1 (en) 2010-10-04 2012-04-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
DK2635257T3 (en) * 2010-11-05 2017-09-04 Novavax Inc Rabies virus-like glycoprotein particles (VLP)
BR112013016239A2 (pt) * 2010-12-22 2016-11-22 Novavax Inc proteínas de hemaglutinina da gripe modificada e seus usos
TWI526539B (zh) * 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
TWI620816B (zh) 2011-03-23 2018-04-11 苜蓿股份有限公司 植物衍生蛋白回收方法
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
CR20190540A (es) 2011-07-11 2022-04-04 Takeda Vaccines Inc FORMULACIONES PARENTERALES DE VACUNAS CONTRA LOS NOVOVIRUS (Divisional 2014-0069)
CN103945863A (zh) 2011-08-01 2014-07-23 爱默蕾大学 包含配体的vlp及其相关方法
EP3275464A1 (en) 2011-08-01 2018-01-31 Emory University Vlps containing ligands and methods related thereto
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6498439B2 (ja) 2011-09-20 2019-04-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
CN104203272A (zh) 2012-01-26 2014-12-10 长角牛疫苗和诊断有限责任公司 复合抗原序列及疫苗
EP2812348A4 (en) 2012-02-07 2015-12-30 Univ Pittsburgh COMPREHENSIVELY OPTIMIZED, WIDE-REACTIVE ANTIGEN FOR H3N2, H2N2 AND B INFLUENZA VIRUSES
SG11201404147YA (en) 2012-02-13 2014-10-30 Univ Pittsburgh Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
RU2485973C1 (ru) * 2012-02-28 2013-06-27 Общество с ограниченной ответственностью "НТфарма" Рекомбинантная трехвалентная вакцина от гриппа человека
US9364530B2 (en) 2012-03-22 2016-06-14 Fraunhofer Usa, Inc. Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
SG11201406153XA (en) 2012-03-30 2014-10-30 Univ Pittsburgh Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6189415B2 (ja) 2012-04-02 2017-08-30 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9938324B2 (en) 2012-05-22 2018-04-10 Cornell University FRET-based reagents and methods for identifying anti-HIV compounds
AU2013274235B2 (en) 2012-06-15 2018-01-18 Samir N. Khleif Cationic lipid vaccine compositions and methods of use
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
WO2014047533A1 (en) * 2012-09-21 2014-03-27 Frank Bedu-Addo Improved vaccine compositions and methods of use
KR101484588B1 (ko) 2012-10-24 2015-01-20 대한민국 개 인플루엔자 ｖｌｐ 백신의 제조방법
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
CN104797594A (zh) 2012-11-27 2015-07-22 高等教育联邦系统-匹兹堡大学 计算优化的广泛反应性h1n1流感抗原
US9371366B2 (en) 2012-12-18 2016-06-21 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
HUE047329T2 (hu) 2013-08-13 2020-04-28 Univ Northwestern Peptiddel konjugált részecskék
CN103467581B (zh) * 2013-08-26 2016-01-20 中国科学院微生物研究所 流感病毒m1蛋白及其编码基因和应用
JP2016530294A (ja) 2013-09-03 2016-09-29 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キメラポリヌクレオチド
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
DK3092309T3 (da) 2014-01-10 2021-04-12 Medicago Inc Cpmv-forstærkerelementer
HUE069802T2 (hu) 2014-04-23 2025-04-28 Modernatx Inc Nukleinsav vakcinák
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10525122B2 (en) 2014-07-18 2020-01-07 Km Biologics Co., Ltd. Vaccine containing virus-like particles
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR101745472B1 (ko) 2015-04-15 2017-06-12 대한민국 조류인플루엔자 바이러스의 세포 감염을 저해하는 물질을 선별하는 방법
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
US10494613B2 (en) * 2015-08-28 2019-12-03 Wisconsin Alumni Research Foundation (Warf) Generation of infectious influenza viruses from virus-like particles
US10426829B2 (en) 2015-09-03 2019-10-01 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
US10391163B2 (en) * 2015-09-10 2019-08-27 Academia Sinica Bird flu vaccine combination comprising virus-like particles and novel adjuvants
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
JP7285220B2 (ja) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
ES2923133T3 (es) 2017-08-04 2022-09-23 Hospital For Sick Children Plataforma de nanopartículas para el suministro de anticuerpos y vacunas
CN107353328A (zh) * 2017-08-23 2017-11-17 上海市动物疫病预防控制中心 一种重组的h9n2亚型禽流感病毒样颗粒及其制备方法和用途
CN107488216B (zh) * 2017-09-06 2020-11-10 中国人民解放军军事医学科学院微生物流行病研究所 一种流感病毒通用疫苗及其制备方法与应用
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
CN110240634B (zh) * 2018-03-08 2022-09-06 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
CN110575538B (zh) * 2018-06-11 2022-08-19 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
CN109097341B (zh) * 2018-08-28 2021-09-24 青岛农业大学 一种同时表达ha和hef的复制缺陷型重组流感病毒
EP3851120A4 (en) 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
JP7662157B2 (ja) 2019-02-08 2025-04-15 ウィスコンシン アルムニ リサーチ ファンデイション ヒト化細胞系
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
US11739303B2 (en) 2020-01-24 2023-08-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized NA
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN113461786B (zh) * 2020-03-30 2022-09-13 普莱柯生物工程股份有限公司 一种禽流感病毒样颗粒疫苗、及其制备方法和应用
CN113398259A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552758A (en) 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
DE69533693T2 (de) 1994-02-24 2005-12-22 Novavax Inc.(n.d.Ges.d.Staates Delaware) Impfstoffe, die paucilamelläre Lipidvesikel als Adjuvans enthalten
AU3760495A (en) 1994-09-30 1996-04-26 Aviron Chimeric Influenza Virus And Electroporation Method
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5945489A (en) 1997-09-19 1999-08-31 Ashland, Inc. Liquid oligomers containing unsaturation
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
DK1294892T3 (da) 2000-06-23 2008-01-28 Wyeth Corp Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)
US6513184B1 (en) 2000-06-28 2003-02-04 S. C. Johnson & Son, Inc. Particle entrapment system
DE60224843T2 (de) * 2001-12-07 2009-01-08 Crucell Holland B.V. Herstellung von viren, virusisolaten, und impfstoffen
WO2003051835A2 (en) 2001-12-18 2003-06-26 Proteologics, Inc. Methods and compositions for the inhibition of viral release
US8551756B2 (en) 2003-07-11 2013-10-08 Novavax, Inc. Avian influenza chimeric VLPS
US8080255B2 (en) 2003-07-11 2011-12-20 Novavax Inc. Functional influenza virus like particles (VLPs)
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
US8992939B2 (en) * 2003-07-11 2015-03-31 Novavax, Inc. Highly efficient influenza matrix (M1) proteins

Similar Documents

Publication Publication Date Title
JP2013216685A5 (enExample)
Russell Hemagglutinin stability and its impact on influenza A virus infectivity, pathogenicity, and transmissibility in avians, mice, swine, seals, ferrets, and humans
Francis et al. Back to the future for influenza preimmunity—Looking back at influenza virus history to infer the outcome of future infections
López-Macías et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico
Dong et al. Status and challenges for vaccination against avian H9N2 influenza virus in China
Kang et al. Influenza virus-like particles as pandemic vaccines
Wu et al. Structural biology of influenza hemagglutinin: An amaranthine adventure
Bright et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle
Jazayeri et al. Development of universal influenza vaccines targeting conserved viral proteins
Bardiya et al. Influenza vaccines: recent advances in production technologies
Li et al. Influenza and universal vaccine research in China
Zheng et al. Development of universal influenza vaccines based on influenza virus M and NP genes
López-Macías Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic
Sekiya et al. Selecting and using the appropriate influenza vaccine for each individual
JP2017035093A5 (enExample)
Liu et al. Virus like particle-based vaccines against emerging infectious disease viruses
Pushko et al. Influenza virus like particles (VLPs): opportunities for H7N9 vaccine development
Wiersma et al. Developing universal influenza vaccines: hitting the nail, not just on the head
HRP20171213T1 (hr) Glikoproteinske čestice nalik virusu (vlp) bjesnoće
Perotti et al. Virus-like particles and nanoparticles for vaccine development against HCMV
CN104185476A (zh) 流感病毒疫苗及其应用
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
Valero-Pacheco et al. Antibody persistence in adults two years after vaccination with an H1N1 2009 pandemic influenza virus-like particle vaccine
Rodriguez et al. Comparative study of the temperature sensitive, cold adapted and attenuated mutations present in the master donor viruses of the two commercial human live attenuated influenza vaccines
Zhang Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines